[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Brainstorm Cell Theraputc (BCLI)

Brainstorm Cell Theraputc (BCLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 8,387
  • Shares Outstanding, K 11,035
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,310 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.64
  • Most Recent Earnings $-0.19 on 05/15/26
  • Next Earnings Date 08/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) +293,923.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6001 +38.23%
on 05/26/26
0.8500 -2.41%
on 06/08/26
+0.1349 (+19.42%)
since 05/08/26
3-Month
0.6001 +38.23%
on 05/26/26
0.9699 -14.48%
on 03/24/26
+0.1295 (+18.50%)
since 03/10/26
52-Week
0.4589 +80.76%
on 02/13/26
1.3300 -37.63%
on 06/11/25
-0.4205 (-33.64%)
since 06/10/25

Most Recent Stories

More News
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

Former FDA Associate Commissioner Peter Pitts and BrainStorm's Chaim Lebovits argue that regulation must keep pace with advances in biomarkers, AI, cell therapy and precision medicine

BCLI : 0.8295 (+9.14%)
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment

BCLI : 0.8295 (+9.14%)
BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

$2.4 Million in H1 2026 Capital Raises Ahead of Phase 3b ENDURANCE Trial

BCLI : 0.8295 (+9.14%)
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK , May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial...

BCLI : 0.8295 (+9.14%)
BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence

BCLI : 0.8295 (+9.14%)
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has...

BCLI : 0.8295 (+9.14%)
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market

NEW YORK , Feb. 20, 2026 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced it has...

BCLI : 0.8295 (+9.14%)
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial...

BCLI : 0.8295 (+9.14%)
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BCLI : 0.8295 (+9.14%)
Halper Sadeh LLC Encourages Brainstorm Cell Therapeutics Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BCLI : 0.8295 (+9.14%)

Business Summary

BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

See More

Key Turning Points

3rd Resistance Point 0.9497
2nd Resistance Point 0.8898
1st Resistance Point 0.8597
Last Price 0.8295
1st Support Level 0.7697
2nd Support Level 0.7098
3rd Support Level 0.6797

See More

52-Week High 1.3300
Fibonacci 61.8% 0.9972
Fibonacci 50% 0.8945
Last Price 0.8295
Fibonacci 38.2% 0.7917
52-Week Low 0.4589

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.